FDA Approval of Subcutaneous Nivolumab

Panelists discuss the FDA approval of subcutaneous nivolumab based on the CheckMate-67T trial findings, highlighting its potential to improve patient convenience and treatment adherence while maintaining efficacy in the treatment of melanoma.

Panelists discuss common adverse events associated with subcutaneous nivolumab, emphasizing the importance of monitoring for immune-related adverse effects and managing them proactively to ensure patient safety and treatment adherence.